pa href="https://www.yahoo.com/news/bayer-j-js-heart-drug-xarelto-fails-trial-125910963--finance.html"img src="" width="130" height="86" alt="Bayer, JJ#39;s heart drug Xarelto fails trial to widen use" align="left" title="Bayer, JJ#39;s heart drug Xarelto fails trial to widen use" border="0" /aBayer and Johnson Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit. Participants in the so-called Mariner study had previously been admitted to hospital for a range of conditions that are associated with a higher risk of venous thromboembolism, such as heart failure, acute respiratory disease, ischemic stroke or infections. Bayer reported 3.3 billion euros ($3.77 billion) in Xarelto revenues last year, mainly from stroke prevention in the elderly, and expects annual sales to rise above 5 billion euros.pbr clear="all"
